Lataa...
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system. One of the most widely used chemotherapeutic drugs for GBM is temozolomide, which is a DNA-alkylating agent and its efficacy is dependent on MGMT methylation status. Little progress...
Tallennettuna:
| Julkaisussa: | Mol Cancer |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5463420/ https://ncbi.nlm.nih.gov/pubmed/28592260 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-017-0670-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|